Original language | English (US) |
---|---|
Pages (from-to) | 520-526 |
Number of pages | 7 |
Journal | Gastroenterology |
Volume | 163 |
Issue number | 2 |
DOIs | |
State | Published - Aug 2022 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Gastroenterology, Vol. 163, No. 2, 08.2022, p. 520-526.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Reducing the Burden of Colorectal Cancer
T2 - AGA Position Statements
AU - Lieberman, David
AU - Ladabaum, Uri
AU - Brill, Joel V.
AU - May, Folasade P.
AU - Kim, Lawrence S.
AU - Murphy, Caitlin
AU - Wender, Richard
AU - Teixeira, Kathleen
N1 - Funding Information: Conflicts of interest These authors disclose the following: David Lieberman: Geneoscopy and ColoWrap (Scientific Advisory Board). Uri Ladabaum: UniversalDx, Lean Medical (advisory board), Medtronic, Clinical Genomics, Guardant Health, Freenome, and Leerink (consultant). Joel V. Brill: Accomplish Health, Alimetry, Allara Health, AnX Robotica, Arch Therapeutics, Biotax, Boomerang Medical, Brightline, Calyx, Capsovision, Check Cap, Clexio, Curology, Docbot, Echosens, Endogastric Solutions, evoEndo, Family First, FDNA, Food Marble, Freespira, Gala Therapeutics, Gamma Tile, Glaukos, gTech Medical, Gynesonics, HBox, Hello Heart, HyGIeaCare, iOR Partners, Impedimed, iRenix, IronRod Health, Johnson & Johnson, Lantheus, LeMinou, Lumen, Mainstay Medical, MaternaMed, Medtronic, Mightier, Motus GI, Neuraxis, Neuspira, OncoSil Medical, Optellum, Palette Life Sciences, Perry Health, Perspectum, Red Ventures, Reflexion, Respira Labs, Salaso, Smith+Nephew, SonarMD, Sonic Incytes, Stage Zero Life Sciences, Steris, Sword Health, Tabula Rosa Health Care, Twin Health, Ultrasight, Vertos Medical, WL Gore (consultant), Accomplish Health, AnX Robotica, Capsovision, Donsini Health, Hbox, Hello Heart, HyGIeaCare, Restech, Perry Health, StageZero Life Sciences, and SonarMD (options/warrants). Folasade P. May: Takeda, Medtronic and Freenome (consultant) and receives grant support from Exact Sciences. The remaining authors disclose no conflicts. Funding Information: David Lieberman: Planning and developing the paper, drafting of each position statement, background research to develop evidence to support each statement, editing document after receiving feedback from the other authors. Uri Ladabaum: Developed models to demonstrate lowered incidence and mortality of colorectal cancer referenced in the paper, providing input and guidance to the position statements, providing evidence and to help support the statements. Joel V. Brill: Providing input and guidance to the position statements, providing evidence to help support the statements. Folasade P. May: Providing input and guidance to the position statements, providing evidence to help support the statements. Larry Kim: Providing input and guidance to the position statements, providing evidence to help support the statements. Caitlin Murphy: Providing input and guidance to the position statements, providing evidence to help support the statements. Richard Wender: Providing input and guidance to the position statements, providing evidence to help support the statements. Kathleen Teixeira: Providing input and guidance to the position statements, providing evidence to help support the statements. Conflicts of interest These authors disclose the following: David Lieberman: Geneoscopy and ColoWrap (Scientific Advisory Board). Uri Ladabaum: UniversalDx, Lean Medical (advisory board), Medtronic, Clinical Genomics, Guardant Health, Freenome, and Leerink (consultant). Joel V. Brill: Accomplish Health, Alimetry, Allara Health, AnX Robotica, Arch Therapeutics, Biotax, Boomerang Medical, Brightline, Calyx, Capsovision, Check Cap, Clexio, Curology, Docbot, Echosens, Endogastric Solutions, evoEndo, Family First, FDNA, Food Marble, Freespira, Gala Therapeutics, Gamma Tile, Glaukos, gTech Medical, Gynesonics, HBox, Hello Heart, HyGIeaCare, iOR Partners, Impedimed, iRenix, IronRod Health, Johnson & Johnson, Lantheus, LeMinou, Lumen, Mainstay Medical, MaternaMed, Medtronic, Mightier, Motus GI, Neuraxis, Neuspira, OncoSil Medical, Optellum, Palette Life Sciences, Perry Health, Perspectum, Red Ventures, Reflexion, Respira Labs, Salaso, Smith+Nephew, SonarMD, Sonic Incytes, Stage Zero Life Sciences, Steris, Sword Health, Tabula Rosa Health Care, Twin Health, Ultrasight, Vertos Medical, WL Gore (consultant), Accomplish Health, AnX Robotica, Capsovision, Donsini Health, Hbox, Hello Heart, HyGIeaCare, Restech, Perry Health, StageZero Life Sciences, and SonarMD (options/warrants). Folasade P. May: Takeda, Medtronic and Freenome (consultant) and receives grant support from Exact Sciences. The remaining authors disclose no conflicts.
PY - 2022/8
Y1 - 2022/8
UR - http://www.scopus.com/inward/record.url?scp=85134574958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134574958&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2022.05.011
DO - 10.1053/j.gastro.2022.05.011
M3 - Article
C2 - 35715380
AN - SCOPUS:85134574958
SN - 0016-5085
VL - 163
SP - 520
EP - 526
JO - Gastroenterology
JF - Gastroenterology
IS - 2
ER -